Effect of rituximab combined with GDP regimen in the treatment of patients with non-Hodgkin's lymphoma and its influence on immune function
Objective To investigate the effect of rituximab combined with gemcitabine+cisplatin+dexamethasone(GDP)regimen in the treatment of patients with non-Hodgkin's lymphoma and its influence on immune function.Methods A total of 106 patients with non-Hodgkin's lymphoma admitted in our hospital from March 2020 to August 2022 were selected and divided into control group(53 cases)and observation group(53 cases)according to different treatment schemes.The control group was treated with GDP regimen,and the observation group was treated with rituximab on the basis of the control group.The therapeutic effects of the two groups were compared.Results The disease control rate(DCR)of the observation group was 96.23%,which was higher than 84.91%of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of immunoglobulin A(IgA),immunoglobulin G(IgG),immunoglobulin M(IgM),complement C3,complement C4,vascular endothelial growth factor(VEGF)and thymidine kinase-1(TK-1)in the observation group were lower than those in the control group,and the difference were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Rituximab combined with GDP regimen is effective in the treatment of patients with non-Hodgkin's lymphoma,it can improve immune function,reduce serum tumor markers levels,and has high drug safety.
NETL
NSTL
万方数据
